Literature DB >> 7013775

Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension.

D N Guadagni, H Ikram, A H Maslowski.   

Abstract

An infusion of prostacyclin (PGI2) in four patients with pulmonary hypertension resulted in a dose-related decrease in the systemic and pulmonary vascular resistance and an increase in cardiac output. No selectivity for the pulmonary vasculature was observed and the drug was not therapeutically beneficial.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7013775      PMCID： PMC482538          DOI： 10.1136/hrt.45.4.385

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


  16 in total

1.  Primary pulmonary hypertension favorable effect of isoproterenol.

Authors:  U R Shettigar; H N Hultgren; M Specter; R Martin; D H Davies
Journal:  N Engl J Med       Date:  1976-12-16       Impact factor: 91.245

2.  Generation of prostacyclin by lungs in vivo and its release into the arterial circulation.

Authors:  R J Gryglewski; R Korbut; A Ocetkiewicz
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

3.  Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension.

Authors:  F S Daoud; J T Reeves; D B Kelly
Journal:  Am J Cardiol       Date:  1978-11       Impact factor: 2.778

4.  Clinical primary pulmonary hypertension: three pathologic types.

Authors:  W D Edwards; J E Edwards
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

5.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

6.  Diazoxide in treatment of primary pulmonary hypertension.

Authors:  S W Wang; J E Pohl; D J Rowlands; E G Wade
Journal:  Br Heart J       Date:  1978-05

7.  Verapamil and pulmonary hypertension.

Authors:  K Landmark; A M Refsum; S Simonsen; O Storstein
Journal:  Acta Med Scand       Date:  1978

8.  Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2.

Authors:  P J Kadowitz; B M Chapnick; L P Feigen; A L Hyman; P K Nelson; E W Spannhake
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1978-09

9.  Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension.

Authors:  J Szczeklik; J S Dubiel; M Mysik; Z Pyzik; R Krol; T Horzela
Journal:  Br Heart J       Date:  1978-12

10.  Longterm favorable effect of oxygen administration on a patient with primary pulmonary hypertension.

Authors:  Y Nagasaka; H Akutsu; Y S Lee; S Fujimoto; J Chikamori
Journal:  Chest       Date:  1978-09       Impact factor: 9.410
View more
  4 in total

1.  Effects of prostaglandin E1 and other vasodilator agents in pulmonary hypertension of scleroderma.

Authors:  M Baron; G Skrinskas; R Hyland; M B Urowitz
Journal:  Br Heart J       Date:  1982-09

2.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

3.  Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus.

Authors:  A Pines; N Kaplinsky; E Goldhammer; D Olchovsky; O Frankl
Journal:  Clin Rheumatol       Date:  1982-12       Impact factor: 2.980

Review 4.  Prostanoid therapies in the management of pulmonary arterial hypertension.

Authors:  Barbara L LeVarge
Journal:  Ther Clin Risk Manag       Date:  2015-03-31       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.